Having trouble accessing articles? Reset your cache.

Interest in carbohydrate antigens grows with Siamab acquisition

Siamab's acquisition by an undisclosed pharma is the latest example of pharma's growing interest in targeting sugar groups to treat cancer. The announcement comes less than two years after the biotech teamed up with Boehringer to go after carbohydrate antigens.

Siamab Therapeutics

Read the full 412 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE